SUPERNUS PHARMACEUTICALS, INC. Gain (Loss) on Extinguishment of Debt
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Gain (Loss) on Extinguishment of Debt of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2020-02-28
- SUPERNUS PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for the quarter ending 2017-12-31 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for the quarter ending 2017-09-30 was -$91.00K.
- SUPERNUS PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for the quarter ending 2017-06-30 was -$103.00K.
- SUPERNUS PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for the quarter ending 2017-03-31 was -$101.00K.
- SUPERNUS PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for fiscal 2019 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for fiscal 2018 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for fiscal 2017 was -$295.00K.
- SUPERNUS PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for fiscal 2016 was -$671.00K.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-02-28 | |||
| 2018-12-31 | $0.00 10-K · filed 2020-02-28 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | -$91.00K derived: sum of 2 quarters · filed 2020-02-28 | -$194.00K derived: sum of 3 quarters · filed 2020-02-28 | -$295.00K 10-K · filed 2020-02-28 |
| 2017-09-30 | -$91.00K 10-Q · filed 2018-11-09 | -$194.00K derived: sum of 2 quarters · filed 2018-11-09 | -$295.00K 10-Q · filed 2018-11-09 | -$584.00K derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | -$103.00K 10-Q · filed 2018-08-09 | -$204.00K 10-Q · filed 2018-08-09 | -$493.00K derived: sum of 3 quarters · filed 2019-03-01 | -$493.00K derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | -$101.00K 10-Q · filed 2018-05-10 | -$390.00K derived: sum of 2 quarters · filed 2019-03-01 | -$390.00K derived: sum of 3 quarters · filed 2019-03-01 | -$390.00K derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | -$289.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | -$289.00K derived: sum of 2 quarters · filed 2019-03-01 | -$289.00K derived: sum of 3 quarters · filed 2019-03-01 | -$671.00K 10-K · filed 2019-03-01 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $0.00 derived: sum of 2 quarters · filed 2017-11-09 | -$382.00K 10-Q · filed 2017-11-09 | -$320.00K derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$382.00K 10-Q · filed 2017-08-03 | -$320.00K derived: sum of 3 quarters · filed 2018-03-01 | -$345.00K derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | -$382.00K 10-Q · filed 2017-05-09 | -$320.00K derived: sum of 2 quarters · filed 2018-03-01 | -$345.00K derived: sum of 3 quarters · filed 2018-03-01 | -$586.00K derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $62.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-01 | $37.00K derived: sum of 2 quarters · filed 2018-03-01 | -$204.00K derived: sum of 3 quarters · filed 2018-03-01 | -$2.34M 10-K · filed 2018-03-01 |
| 2015-09-30 | -$25.00K 10-Q/A · filed 2017-01-20 | -$266.00K derived: sum of 2 quarters · filed 2017-01-23 | -$2.40M 10-Q/A · filed 2017-01-20 | -$2.40M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-06-30 | -$241.00K 10-Q/A · filed 2017-01-23 | -$2.38M 10-Q/A · filed 2017-01-23 | -$2.38M derived: sum of 3 quarters · filed 2017-03-16 | -$3.23M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-03-31 | -$2.13M 10-Q/A · filed 2017-01-20 | -$2.13M derived: sum of 2 quarters · filed 2017-03-16 | -$2.99M derived: sum of 3 quarters · filed 2017-03-16 | -$3.03M derived: sum of 4 quarters · filed 2017-03-16 |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2017-03-16 | -$860.00K derived: sum of 2 quarters · filed 2017-03-16 | -$899.00K derived: sum of 3 quarters · filed 2017-03-16 | -$2.59M 10-K · filed 2017-03-16 |
| 2014-09-30 | -$860.00K 10-Q/A · filed 2017-01-20 | -$899.00K derived: sum of 2 quarters · filed 2017-01-20 | -$2.59M 10-Q/A · filed 2017-01-20 | -$10.98M derived: sum of 4 quarters · filed 2017-01-20 |
| 2014-06-30 | -$39.00K 10-Q · filed 2015-08-07 | -$1.73M 10-Q · filed 2015-08-07 | -$10.12M derived: sum of 3 quarters · filed 2017-01-20 | -$10.12M derived: sum of 4 quarters · filed 2017-01-20 |
| 2014-03-31 | -$1.69M 10-Q · filed 2015-05-06 | -$10.08M derived: sum of 2 quarters · filed 2017-01-20 | -$10.08M derived: sum of 3 quarters · filed 2017-01-20 | -$11.24M derived: sum of 4 quarters · filed 2017-01-20 |
| 2013-12-31 | -$8.39M derived: 10-K/A 12 month − 10-Q 9 month · filed 2017-01-20 | -$8.39M derived: sum of 2 quarters · filed 2017-01-20 | -$9.55M derived: sum of 3 quarters · filed 2017-01-20 | -$9.55M 10-K/A · filed 2017-01-20 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | -$1.16M derived: sum of 2 quarters · filed 2014-11-12 | -$1.16M 10-Q · filed 2014-11-12 | |
| 2013-06-30 | -$1.16M 10-Q · filed 2014-08-12 | -$1.16M 10-Q · filed 2014-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |